RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
  AIDS
  Anthrax
  Dengue
  Ebola
  HCV
  Influenza
  Leishmaniasis
  Malaria
   Plasmodium
  MRSA
  Mumps
  Pertussis
  Prion Diseases
  SARS
  Shigella
  Small Pox
  Tuberculosis
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Malaria Channel

subscribe to Malaria newsletter
Latest Research : Infectious Diseases : Malaria

   EMAIL   |   PRINT
LMP-420 reduces endothelial cell activation in cerebral malaria

Aug 23, 2005 - 8:11:00 PM
The authors caution that the experimental in vitro results do not necessarily predict potential efficacy in either animal models or humans, especially since in their model the LMP-420 had to be given before the disease process was established.

 
[RxPG] In a paper published online in PLoS Medicine researchers from Marseille describe the effects of a new compound that may be a future treatment for patients with cerebral malaria. The compound¡XLMP-420¡Xinhibits two of the molecules produced in the brain when affected by cerebral malaria.

Cerebral malaria is a complication that can occur in malaria caused by the parasite Plasmodium falciparum. In cerebral malaria, the parasites infect the red blood cells that accumulate within the very small capillaries that flow through the tissues of the brain. Even when treated, cerebral malaria has a fatality rate of 15% or more.

Using an in vitro model of cerebral malaria, the researchers, led by George Grau, found that LMP-420 potently reduced the activation of endothelial cells (cells that line the small blood vessels), how well malaria-infected red blood cells stuck to these endothelial cells, and the release of micro particles from the same cells¡Xthree major features of cerebral malaria.

The authors caution that the experimental in vitro results do not necessarily predict potential efficacy in either animal models or humans, especially since in their model the LMP-420 had to be given before the disease process was established. Nevertheless, this avenue of research is a promising one to explore further.



Publication: Citation: Wassmer SC, Cianciolo GJ, Combes V, Grau GE (2005) Inhibition of endothelial activation: A new way to treat cerebral malaria? PLoS Med 2(9): e245.
On the web: http://www.plosmedicine.org/ 

Advertise in this space for $10 per month. Contact us today.


Related Malaria News
Disease control with current interventions has greater impact on malaria than global warming
Target Site for Developing Mosquito Pesticides Discovered
Retina can provide a very reliable way of diagnosing cerebral malaria
New findings could lead to vaccine for severe malaria
AgDscam gene Holds the Key to Broad-Based Pathogen Recognition
Genes responsible for malaria parasite's survival pin pointed
Mosquito immune system examined
The Haptoglobin Genotype Connection with Childhood Anemia in a Malaria-Endemic Region
Mosquitoes that could help combat malaria!
Malaria parasite plasmodium impairs key immune system cells

Subscribe to Malaria Newsletter

Enter your email address:


 Additional information about the news article
All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere¡Xto read, download, redistribute, include in databases, and otherwise use subject only to the condition that the original authorship and source are properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)